IMW 2021 | Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myeloma
Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, presents updated data from the Phase II MASTER study (NCT03224507) investigating daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous stem cell transplant (ASCT), and measurable residual disease (MRD) response-adapted treatment for newly diagnosed myeloma. Dr Callander discusses the rationale for the trial and summarizes the key findings. MRD negativity rates, as determined by next-generation sequencing (NGS), were found to be 35% after induction therapy, 65% after transplant, and over 80% for patients who continued with further treatment. The study was also enriched with high-risk patients to investigate the response rates associated with this Dara-KRd MRD-adaptive approach in this sub-set of patients. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
